Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients

Oral Anticoagulant Bleeding Rate and Discontinuation and Adherence Patterns in Non-Valvular Atrial Fibrillation (NVAF) Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02792335

Enrollment

28000

Registered

2016-06-07

Start date

2012-01-31

Completion date

2014-08-31

Last updated

2016-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Brief summary

To describe the rate of discontinuation among Non-Valvular Atrial Fibrillation (NVAF) patients who were on warfarin and have switched to the Novel oral anticoagulants(NOACs).

Interventions

DRUGapixaban

DRUGdabigatran

DRUGrivaroxaban

DRUGwarfarin

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Individuals with NVAF who were on warfarin and have switched to the NOACs (dabigatran, rivaroxaban and apixaban) within the study period January 01, 2013 through March 31, 2014 * Individuals ≥18 years old on the index date * At least 1 year of baseline period with history of continuous warfarin use in the baseline period for at least 3 months immediately before the index date * At least 1 diagnosis of AF in the 12 months prior to index date * Continuous eligibility with medical and pharmacy benefits for at least 12 months before the index date through 1 month after the index date

Exclusion criteria

* Individuals with a diagnosis of valvular heart disease or cardiac surgery during the 12 months prior to index date

Design outcomes

Primary

Measure	Time frame
Discontinuation rate of patients with prior warfarin use	up to 31 months
Rate of major bleeding events of patients with prior warfarin use	up to 31 months
Rate of hospitalization due to major bleeding events of patients with warfarin use	up to 31 months
Discontinuation rate of patients who were naïve to oral anticoagulant	up to 31 months
Rate of major bleeding events of patients who were naïve to oral anticoagulant	up to 31 months
Rate of hospitalization due to major bleeding events of patients who were naïve to oral anticoagulant	up to 31 months

Secondary

Measure	Time frame
All-Cause Healthcare per patient per month (PPPM) cost	up to 31 months
Rate of All-Cause Hospitalization	up to 31 months
AF-related Healthcare per patient per month (PPPM) cost	up to 31 months
Rate of Atrial Fibrillation(AF)-Related Hospitalization	up to 31 months
Rate of All-Cause Any Rehospitalization	up to 31 months
Rate of AF-Related Any Rehospitalization	up to 31 months
Rate of All-Cause Early Hospitalization	up to 31 months
Rate of AF-Related Early Hospitalization	up to 31 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026